Traumatic optic neuropathy (TON) refers to optic nerve damage caused by trauma, leading to partial or complete loss of vision. The primary treatment options, such as hormonal therapy and surgery, have limited efficacy. Pituitary adenylate cyclase-activating polypeptide 38 (PACAP38), a functional endogenous neuroprotective peptide, has emerged as a promising therapeutic agent. In this study, we used rat retinal ganglion cell (RGC) exosomes as nanosized vesicles for the delivery of PACAP38 loaded via the exosomal anchor peptide CP05 (EXO ). EXO showed greater uptake efficiency and than PACAP38. The results showed that EXO significantly enhanced the RGC survival rate and retinal nerve fiber layer thickness in a rat TON model. Moreover, EXO significantly promoted axon regeneration and optic nerve function after injury. These findings indicate that EXO can be used as a treatment option and may have therapeutic implications for patients with TON.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055942 | PMC |
http://dx.doi.org/10.3389/fcell.2021.659783 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!